Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Solvay Pharma India Ltd. (Amalgamated) (532447)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532447 NSE: Pharmaceuticals & Drugs | Small Cap | Solvay Pharma Share Price
BSE Share Price
Not Listed
Not Listed
Solvay Pharma India Ltd. (Amalgamated) (532447)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532447 NSE: Pharmaceuticals & Drugs | Small Cap | Solvay Pharma Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹1,081 Cr.
Current Price
₹0
52-Week Low / High
₹1,665 / 3,200
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.2
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
21.93%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
88.85%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹5.1 Cr.
Face Value
₹10
All Time Low / High
₹87.50 / 3599.60
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'02 | Dec'02 | Dec'03 | Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 77.6% | 52.5% | 40.8% | 73.5% | 46.8% | 39.4% | 50.8% | 51.2% | 50.7% | 51.3% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 78.1 | 82.3 | 96.6 | 116 | 130 | 144 | 168 | 200 | 242 | 295 | 312 |
| Sales YoY Gr. | - | 5.3% | 17.4% | 20.3% | 11.7% | 11.1% | 16.4% | 19.4% | 20.7% | 21.9% | - |
| Adj EPS ⓘ | 15.9 | 20.9 | 15.5 | 34.3 | 35.1 | 37.3 | 55 | 63.8 | 77.1 | 99.5 | 100.5 |
| YoY Gr. | - | 31.9% | -25.9% | 121.3% | 2.4% | 6.2% | 47.5% | 16.1% | 20.9% | 29.1% | - |
| BVPS (₹) ⓘ | 39.6 | 69.8 | 64.7 | 105.3 | 134.6 | 162.5 | 171.9 | 216.4 | 257.6 | 328.6 | 350.8 |
| Adj Net Profit ⓘ | 8 | 10.6 | 7.8 | 17.3 | 17.7 | 18.8 | 27.8 | 32.2 | 39 | 50.3 | 51 |
| Cash Flow from Ops. ⓘ | 10 | 20.1 | -2.3 | 21.5 | 17.3 | 14.7 | 26.6 | -6.7 | 69.7 | 27.5 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | -1.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 15.9% | 17.8% | 20.7% | 21.9% | ||||
| Adj EPS ⓘ | 22.6% | 23.2% | 21.9% | 29.1% | ||||
| BVPSⓘ | 26.5% | 19.6% | 24.1% | 27.6% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'02 | Dec'02 | Dec'03 | Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 48.6 | 34.1 | 26.5 | 40.4 | 29.3 | 25.1 | 32.9 | 32.9 | 32.5 | 34 | 29.6 |
| Op. Profit Mgn % ⓘ | 16.7 | 20.1 | 17.3 | 23.7 | 23.3 | 21.5 | 26.3 | 23.5 | 24.9 | 24.9 | 25.5 |
| Net Profit Mgn % ⓘ | 10.3 | 12.9 | 8.1 | 14.9 | 13.7 | 13.1 | 16.6 | 16.1 | 16.1 | 17.1 | 16.3 |
| Debt to Equity ⓘ | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 77 | 112 | 95 | 90 | 85 | 95 | 92 | 121 | 115 | 95 | 85 |
| Cash Conv. Cycle ⓘ | 21 | 17 | 31 | 35 | 25 | 28 | 21 | 31 | 30 | 23 | 58 |
Valuation of Solvay Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Solvay Pharma India Ltd. (Amalgamated) FAQs
The current trading price of Solvay Pharma on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Solvay Pharma stood at ₹1,081.4 Cr
The latest P/E ratio of Solvay Pharma as of 31-Dec-1969 is 21.30.
The latest P/B ratio of Solvay Pharma as of 31-Dec-1969 is 6.11.
The 52-week high of Solvay Pharma is ₹3,200 and the 52-week low is ₹1,665.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Solvay Pharma is ₹312 ( Cr.) .
Data is not available for this company.
No data found
No data found
About Solvay Pharma India Ltd. (Amalgamated)
Solvay Pharma India (SPIL) was incorporated in 2002 as a consequence of the demerger of pharma business of Duphar-Interfran. Solvay Pharma India has presence in the field of women’s health, gastroenterology, mental health and influenza vaccines. Deeply rooted in these specialty segments SPIL is a leader with its competent products and innovative solutions. The company strives to provide the health care industry with newer & quality products that are effective and safe in areas where clinical need for treatment is most urgent.
Products
Women Health
- arachitol®
- duphaston®
- duvadilan®
- Utrogestan®
- puregon*
- nugon*
- clome*
- Oestrogel®
- bcrip*
Psychiatry / ENT / Neurology
- solspre*
- vertin®
- uvox*
- ebasil*
Gastroenterology
- duphalac®
- creon®
- colospa®
- eldicet®
- pankreoflat®
- udiliv®
Vaccines influvac®
General
- duodil®
- collosal iodine oral
Solvay is an international chemical and pharmaceutical group with headquarters in Brussels. In India, Solvay is present in the pharmaceutical sector through its group company Solvay Pharma India. The company is head quartered at Mumbai and employs more than 450 people throughout India. It operates through two sales divisions and reaches out to its customers across the country through more than 1100 distributors. Currently the company structures itself into 2 Divisions, aided with its dedicated sales force and focusing on specialties and super specialties.
With research as the backbone, most of the products are brand leaders in their respective therapeutic segments. High level of scientific interaction, intense product knowledge enables the team to meet the ever-changing needs of medicine. New Product Introduction is advocated actively and the company plans to launch new products each year in either divisions.
You have 47 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
